ReviewViruses2015
Bacteriophage-derived vectors for targeted cancer gene therapy.
Review in Viruses, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Unlocking the potential of bacteriophage-based therapeutic gene delivery in hepatocellular carcinoma.Journal of the Egyptian National Cancer Institute · 2026Review
- Construction and utilization of a new generation of bacteriophage-based particles, or TPA, for guided systemic delivery of nucleic acids to tumors.Nature protocols · 2026Review
- Phage enabled precision drug delivery: dual function platforms for therapeutics and genetic cargo transport.Frontiers in microbiology · 2026Review
- Targeted treatment of chondrosarcoma with a bacteriophage-based particle delivering a secreted tumor necrosis factor-related apoptosis-inducing ligand.Molecular therapy. Oncology · 2024Article
- Modified Bacteriophage for Tumor Detection and Targeted Therapy.Nanomaterials (Basel, Switzerland) · 2023Review
- Bacteriophage-Mediated Cancer Gene Therapy.International journal of molecular sciences · 2022Review
- Bacteriophages as Solid Tumor Theragnostic Agents.International journal of molecular sciences · 2021Review
- The Many Applications of Engineered Bacteriophages-An Overview.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Article
- Engineered M13 Peptide Carrier Promotes Angiogenic Potential of Patient-Derived Human Cardiac Progenitor Cells and In Vivo Engraftment.Tissue engineering and regenerative medicine · 2020Article
- Initial Steps for the Development of a Phage-Mediated Gene Replacement Therapy Using CRISPR-Cas9 Technology.Journal of clinical medicine · 2020Article
- CRISPR/Cas9: A Potential Life-Saving Tool. What's next?Molecular therapy. Nucleic acids · 2017Article
- Engineering of Bacteriophage T4 Genome Using CRISPR-Cas9.ACS synthetic biology · 2017Article
- Bacteriophage Clinical Use as Antibacterial "Drugs": Utility and Precedent.Microbiology spectrum · 2017Review
- Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Bacteriophage Mediates Efficient Gene Transfer in Combination with Conventional Transfection Reagents.Viruses · 2015Article
- Progresses towards safe and efficient gene therapy vectors.Oncotarget · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cancer gene therapy expanded and reached its pinnacle in research in the last decade. Both viral and non-viral vectors have entered clinical trials, and significant successes have been achieved. However, a systemic administration of a vector, illustrating safe, efficient, and targeted gene delivery to solid tumors has proven to be a major challenge. In this review, we summarize the current progress and challenges in the targeted gene therapy of cancer. Moreover, we highlight the recent developments of bacteriophage-derived vectors and their contributions in targeting cancer with therapeutic genes following systemic administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.